Tech Company Financing Transactions
Eureka Therapeutics Funding Round
Lyell Immunopharma and private investors joined a $45 million Series E venture round for Eureka Therapeutics. The round was announced on 3/18/2020.
Transaction Overview
Company Name
Announced On
3/18/2020
Transaction Type
Venture Equity
Amount
$45,000,000
Round
Series E
Investors
Lyell Immunopharma (Lead Investor) (Rick Klausner)
Proceeds Purpose
The Company will use proceeds from the Series E round to advance its proprietary TCR-mimic and antibody-TCR ARTEMIS programs, including Eureka's anti-AFP ARTEMIS Phase I/II clinical trial in the United States for the treatment of hepatocellular carcinoma (HCC), the predominant type of liver cancer.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
5858 Horton St. 170
Emeryville, CA 94608
USA
Emeryville, CA 94608
USA
Phone
Website
Email Address
Overview
Eureka Therapeutics is focused on developing novel T cell immunotherapies for the treatment of solid tumors. Our unique platform is powered by TCR-like antibodies which recognize previously inaccessible cancer antigens specific for solid tumors.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Cheng Liu
Chief Operating Officer
Vivien Chan
VP - Bus. Development
Hanzhong Li
VP - General Counsel
Victor Shum
Browse more venture capital transactions:
Prev: 3/18/2020: CoreStack venture capital transaction
Next: 3/18/2020: Spectro Cloud venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here come from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs